Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05378386
Other study ID # 2021-11
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 12, 2022
Est. completion date December 2034

Study information

Verified date March 2024
Source Edwards Lifesciences
Contact Edwards THV Clinical Affairs
Phone 949-250-2500
Email THV_CT.gov@Edwards.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting


Description:

This is a single arm, prospective, multicenter post-approval study.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2034
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Native or surgically-repaired RVOT with severe PR 2. Clinically indicated for pulmonary valve replacement 3. Planned for treatment with the Alterra prestent and SAPIEN 3 THV Exclusion Criteria: 1. Inability to tolerate an anticoagulation/antiplatelet regimen 2. Active bacterial endocarditis or other active infections

Study Design


Intervention

Device:
Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).

Locations

Country Name City State
Israel Schneider Children's Medical Center of Israel Petah Tikva
United States Colorado Children's Hospital Aurora Colorado
United States Children's of Alabama Birmingham Alabama
United States Boston Children's Hospital Boston Massachusetts
United States University of Virginia Charlottesville Virginia
United States Cincinnati Children's Hospital Cincinnati Ohio
United States Nationwide Children's Hospital Columbus Ohio
United States Medical City Dallas Dallas Texas
United States Duke University Durham North Carolina
United States Texas Children's Hospital Houston Texas
United States Arkansas Children's Hospital Little Rock Arkansas
United States Cedars Sinai Medical Center Los Angeles California
United States Columbia University New York New York
United States Icahn School of Medicine at Mount Sinai New York New York
United States Advocate Children's Hospital Oak Lawn Illinois
United States UPMC Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States Washington University in St. Louis Saint Louis Missouri
United States Primary Children's Hospital Salt Lake City Utah
United States Rady's Children's Hospital San Diego California
United States Seattle Children's Hospital Seattle Washington
United States Stanford University Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Edwards Lifesciences

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute Device Success Acute Device Success, defined as a non-hierarchical composite of:
Single Alterra deployed in the desired location
Single THV implanted in the desired location within Alterra
Right ventricle-pulmonary artery peak-to-peak gradient < 35 mmHg post-THV implantation
Less than moderate total pulmonary regurgitation (PR) by discharge transthoracic echocardiogram
Free of Alterra/SAPIEN 3 explant at 24 hours post-implantation
24 hours post-procedure
See also
  Status Clinical Trial Phase
Completed NCT02534792 - Early Revalvulation After Fallot Repair Improves Clinical Outcome N/A
Completed NCT00536432 - Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot N/A
Not yet recruiting NCT05485545 - Asynchrony in Operated Tetralogy of Fallot N/A
Completed NCT01941576 - Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot N/A
Active, not recruiting NCT03983512 - PULSTA Transcatheter Pulmonary Valve Pre-Approval Study N/A
Recruiting NCT04581668 - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease N/A
Completed NCT01762124 - Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV) N/A
Active, not recruiting NCT02161471 - Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance
Not yet recruiting NCT05916976 - Repaired Tetralogy of Fallot: Risc Score From MRI & Clinical Data to Predict the Need for Change of Treatment N/A
Recruiting NCT04106479 - NIRS in Congenital Heart Defects - Correlation With Echocardiography
Completed NCT05579964 - The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot Phase 2/Phase 3
Recruiting NCT05236153 - Electroanatomic Interactions Between Transcatheter Pulmonary Valve Prostheses and Anatomic Isthmuses in Repaired Tetralogy of Fallot N/A
Recruiting NCT03049995 - Stress Echo 2020 - The International Stress Echo Study
Completed NCT02586740 - Retrospective Review of Anesthetic Considerations for Pulmonary Artery Rehabilitation N/A
Terminated NCT00564993 - Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot Phase 3
Recruiting NCT05122962 - Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
Completed NCT06097377 - Lymphatic Magnetic Resonance Imaging Abnormalities in Children With Tetralogy of Fallot: A Case-Control Study
Completed NCT03835494 - Analysis of RV-Dysfunction in Fallot Patients N/A
Not yet recruiting NCT03275844 - Physical Capacity and Activity in Children With Congenital Heart Disease N/A
Recruiting NCT02590679 - Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p Phase 2/Phase 3